Citius Oncology Inc.

CTOR | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.05

+$0.01 (+0.48%)

At close: Sep 22, 2026, 3:59 PM ET

$1.07

+$0.02 (+1.90%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

Key Executives

Name	Position
Leonard L. Mazur	Chief Executive Officer, President & Executive Chairman
Jaime Bartushak	Chief Financial Officer & Treasurer
Myron S. Czuczman	Executive Vice President & Chief Medical Officer
Myron Z. Holubiak	Executive Vice Chairman & Secretary

Latest SEC Filings

Date	Type	Title
Jun 01, 2026	424B3	Filing
Jun 01, 2026	8-K	Current Report
May 29, 2026	DEF 14C	Filing
May 29, 2026	S-3	Filing
May 22, 2026	424B3	Filing
May 19, 2026	PRE 14C	Filing
May 15, 2026	8-K	Current Report
May 15, 2026	10-Q	Quarterly Report
May 15, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
May 06, 2026	424B3	Filing

View All SEC Filings ➞

Citius Oncology Inc.

Country	United States
IPO Date	Dec 7, 2022
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	285
CEO	Leonard L. Mazur

Contact Details

11 Commerce Drive Cranford, New York 07016 United States

https://www.citiusonc.com/overview/default.aspx

347-627-0058

Stock Details

Ticker Symbol	CTOR
Exchange	NASDAQ
Fiscal Year	n/a
Reporting Currency	USD
CIK Code	0001851484
CUSIP Number	17331Y109
ISIN Number	US17331Y1091
SIC Code	n/a